Summaries & Associations of Study Results
TR-329 1,2-Epoxybutane
Target Organs and Levels of Evidence
NTP Technical Report Number 329
Produced from Chemtrack Database 09/19/01
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| 1,2-EPOXYBUTANE 106-88-7 |
08/19/86 | FOR PROD'N OF BUTANEDIOLS, GLYCOL ESTERS & ETHERS, PREP'N OF SURFACTANTS & GASOLINE ADDITIVES, INTERMED. FOR POLYMERS, STABILIZER (HSDB 1990). | Inhalation R: 0,200,400, M: 0,50,100 PPM/50 PER GROUP | Battelle Northwest Laboratory |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: CLEAR EVIDENCE | NASAL CAVITY: ADENOMA 0/50 0/50 7/50 | |||
| LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 1/50 1/49 OR ALVEOLAR/BRONCHIOLR CARCINOMA 0/50 1/50 4/49 COMBINED 0/50 2/50 5/49 | ||||
| NON-NEOPLASTIC LESIONS: | NASAL CAVITY: HYPERPLASIA, ADENOMATOUS; INFLAMMATION, NOS; INFLAMMATION, SEROUS, INFLAMMATION, SUPPURATIVE | |||
| FR: EQUIVOCAL EVIDENCE | NASAL CAVITY: ADENOMA 0/50 0/50 2/50 | |||
| NON-NEOPLASTIC LESIONS: | NASAL CAVITY: HYPERPLASIA, ADENOMATOUS; INFLAMMATION, NOS; INFLAMMATION, SEROUS; INFLAMMATION, SUPPURATIVE | |||
| MM: NO EVIDENCE | ||||
| NON-NEOPLASTIC LESIONS: | NASAL CAVITY: INFLAMMATION, CHRONIC | |||
| FM: NO EVIDENCE | ||||
| NON-NEOPLASTIC LESIONS: | NASAL CAVITY: INFLAMMATION, CHRONIC | |||
Web page last updated on February 10, 2006
